Publisher
Springer International Publishing
Reference17 articles.
1. Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, et al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018;14:727–49.
2. Loutradis C, Sarafidis PA, Ortiz A, Ferro CJ. Is our increasing understanding of PCSK9 and Lp(a) metabolism the key to unlocking the paradox of statins ineffectiveness in reducing cardiovascular events in advanced CKD? SN Compr Clin Med. 2022;4:145.
3. Law JP, Pickup L, Pavlovic D, Townend JN, Ferro CJ. Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations. J Hum Hypertens. 2022;33:1–19.
4. Law JP, Price AM, Pickup L, Radhakrishnan A, Weston C, Jones AM, et al. Clinical potential of targeting fibroblast growth factor-23 and alphaKlotho in the treatment of uremic cardiomyopathy. J Am Heart Assoc. 2020;9:e016041.
5. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.